{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:32:15Z","timestamp":1793302335349,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangdong Provincial Medical Research Fund","award":["A2025081"],"award-info":[{"award-number":["A2025081"]}]},{"name":"Guangdong Provincial Science and Technology Planning Project","award":["2023B110009"],"award-info":[{"award-number":["2023B110009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12640-026-00825-y","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:08:54Z","timestamp":1788937734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atorvastatin Shows Limited Disease-Modifying Effects in an A53T \u03b1-Synuclein Mouse Model of Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"44","author":[{"given":"Lijian","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkai","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangfeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiWei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingShu","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"825_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178282","volume":"1007","author":"N Arendt","year":"2025","unstructured":"Arendt N, Kopsida M, Lennern\u00e4s H, Sj\u00f6blom M, Heindryckx F (2025) Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives. Eur J Pharmacol 1007:178282. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178282","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"825_CR2","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","volume":"105","author":"P Bar-On","year":"2008","unstructured":"Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E (2008) Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson\u2019s disease. J Neurochem 105(5):1656\u20131667. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05254.x","journal-title":"J Neurochem"},{"issue":"3","key":"825_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/med.22091","volume":"45","author":"G Bellini","year":"2025","unstructured":"Bellini G, D\u2019Antongiovanni V, Palermo G, Antonioli L, Fornai M, Ceravolo R, Bernardini N, Derkinderen P, Pellegrini C (2025) \u03b1-Synuclein in Parkinson\u2019s disease: from bench to bedside. Med Res Rev 45(3):909\u2013946. https:\/\/doi.org\/10.1002\/med.22091","journal-title":"Med Res Rev"},{"issue":"9","key":"825_CR4","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1093\/brain\/awad150","volume":"146","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Di Lazzaro G, Marino G, Campanelli F, Ghiglieri V (2023) Advances in understanding the function of alpha-synuclein: implications for Parkinson\u2019s disease. Brain 146(9):3587\u20133597. https:\/\/doi.org\/10.1093\/brain\/awad150","journal-title":"Brain"},{"issue":"5688","key":"825_CR5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688):1292\u20131295. https:\/\/doi.org\/10.1126\/science.1101738","journal-title":"Science"},{"issue":"2","key":"825_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000513678","volume":"28","author":"RW Du","year":"2021","unstructured":"Du RW, Bu WG (2021) Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson\u2019s Disease via Inhibition of A1 Reactive Astrocytes. Neuroimmunomodulation 28(2):82\u201389. https:\/\/doi.org\/10.1159\/000513678","journal-title":"Neuroimmunomodulation"},{"issue":"43","key":"825_CR7","doi-asserted-by":"publisher","first-page":"13543","DOI":"10.1523\/jneurosci.4144-09.2009","volume":"29","author":"A Ghosh","year":"2009","unstructured":"Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson\u2019s disease. J Neurosci 29(43):13543\u201313556. https:\/\/doi.org\/10.1523\/jneurosci.4144-09.2009","journal-title":"J Neurosci"},{"key":"825_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106105","volume":"180","author":"Q Huang","year":"2023","unstructured":"Huang Q, Chen C, Chen W, Cai C, Xing H, Li J, Li M, Ma S (2023) Cell type- and region-specific translatomes in an MPTP mouse model of Parkinson\u2019s disease. Neurobiol Dis 180:106105. https:\/\/doi.org\/10.1016\/j.nbd.2023.106105","journal-title":"Neurobiol Dis"},{"issue":"10","key":"825_CR9","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awab292","volume":"144","author":"SH Jeong","year":"2021","unstructured":"Jeong SH, Lee HS, Chung SJ, Yoo HS, Jung JH, Baik K, Lee YH, Sohn YH, Lee PH (2021) Effects of statins on dopamine loss and prognosis in Parkinson\u2019s disease. Brain 144(10):3191\u20133200. https:\/\/doi.org\/10.1093\/brain\/awab292","journal-title":"Brain"},{"issue":"2","key":"825_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14802\/jmd.25008","volume":"18","author":"SH Jeong","year":"2025","unstructured":"Jeong SH, Lee PH (2025) Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson\u2019s Disease. J Mov Disord 18(2):113\u2013126. https:\/\/doi.org\/10.14802\/jmd.25008","journal-title":"J Mov Disord"},{"key":"825_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbi.2022.01.007","volume":"101","author":"AA Karikari","year":"2022","unstructured":"Karikari AA, McFleder RL, Ribechini E, Blum R, Bruttel V, Knorr S, Gehmeyr M, Volkmann J, Brotchie JM, Ahsan F, Haack B, Monoranu CM, Keber U, Yeghiazaryan R, Pagenstecher A, Heckel T, Bischler T, Wischhusen J, Koprich JB, Lutz MB, Ip CW (2022) Neurodegeneration by \u03b1-synuclein-specific T cells in AAV-A53T-\u03b1-synuclein Parkinson\u2019s disease mice. Brain Behav Immun 101:194\u2013210. https:\/\/doi.org\/10.1016\/j.bbi.2022.01.007","journal-title":"Brain Behav Immun"},{"issue":"7","key":"825_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.stem.2023.05.015","volume":"30","author":"MS Kim","year":"2023","unstructured":"Kim MS, Ra EA, Kweon SH, Seo BA, Ko HS, Oh Y, Lee G (2023) Advanced human iPSC-based preclinical model for Parkinson\u2019s disease with optogenetic alpha-synuclein aggregation. Cell Stem Cell 30(7):973\u2013986e911. https:\/\/doi.org\/10.1016\/j.stem.2023.05.015","journal-title":"Cell Stem Cell"},{"issue":"7","key":"825_CR13","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1523\/jneurosci.22-07-02780.2002","volume":"22","author":"D Kirik","year":"2002","unstructured":"Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bj\u00f6rklund A (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22(7):2780\u20132791. https:\/\/doi.org\/10.1523\/jneurosci.22-07-02780.2002","journal-title":"J Neurosci"},{"issue":"4","key":"825_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/0162243917726579","volume":"43","author":"RGW Kirk","year":"2018","unstructured":"Kirk RGW (2018) Recovering The Principles of Humane Experimental Technique: The 3Rs and the Human Essence of Animal Research. Sci Technol Hum Values 43(4):622\u2013648. https:\/\/doi.org\/10.1177\/0162243917726579","journal-title":"Sci Technol Hum Values"},{"issue":"2","key":"825_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.expneurol.2009.11.015","volume":"221","author":"AO Koob","year":"2010","unstructured":"Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E (2010) Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 221(2):267\u2013274. https:\/\/doi.org\/10.1016\/j.expneurol.2009.11.015","journal-title":"Exp Neurol"},{"key":"825_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2012.06.050","volume":"1471","author":"A Kumar","year":"2012","unstructured":"Kumar A, Sharma N, Gupta A, Kalonia H, Mishra J (2012) Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res 1471:13\u201322. https:\/\/doi.org\/10.1016\/j.brainres.2012.06.050","journal-title":"Brain Res"},{"key":"825_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041944","author":"A Lodge","year":"2026","unstructured":"Lodge A, Agin-Liebes J (2026) \u03b1-Synuclein biomarkers for Parkinson\u2019s disease. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a041944","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"8","key":"825_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14888","volume":"30","author":"A Mady","year":"2024","unstructured":"Mady A, Nabil Y, Daoud A, Alnajjar AZ, Alsalloum T, Marwan M, Abdelmeseh M, Elsayed M, Krayim A, Alaa M, Masoud M, Bushara N, Faisal R, Ahmed H, Saad M, Belabaci Z, Barrett MJ, Berman B, Negida A (2024) Determining the role of statins in Parkinson\u2019s disease risk reduction and disease modification: a comprehensive meta-analysis of 4 million participants\u2019 data. CNS Neurosci Ther 30(8):e14888. https:\/\/doi.org\/10.1111\/cns.14888","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"825_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s12640-017-9840-8","volume":"33","author":"NF Marques","year":"2018","unstructured":"Marques NF, Castro AA, Mancini G, Rocha FL, Santos ARS, Prediger RD, De Bem AF, Tasca CI (2018) Atorvastatin prevents early oxidative events and modulates inflammatory mediators in the striatum following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats. Neurotox Res 33(3):549\u2013559. https:\/\/doi.org\/10.1007\/s12640-017-9840-8","journal-title":"Neurotox Res"},{"issue":"1","key":"825_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D (2011) Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146(1):37\u201352. https:\/\/doi.org\/10.1016\/j.cell.2011.06.001","journal-title":"Cell"},{"key":"825_CR21","doi-asserted-by":"publisher","unstructured":"Mesentier-Louro LA, Goldman C, Ndayisaba A, Buonfiglioli A, Rooklin RB, Schuldt BR, Uchitelev A, Khurana V, Blanchard JW (2025) Cholesterol-mediated lysosomal dysfunction in APOE4 astrocytes promotes \u03b1-synuclein pathology in human brain tissue. bioRxiv. https:\/\/doi.org\/10.1101\/2025.02.09.637107","DOI":"10.1101\/2025.02.09.637107"},{"key":"825_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136001","author":"R Mohammadi","year":"2025","unstructured":"Mohammadi R, Shirazi M, Sadat-Madani SF, Yeo Cheng Long MZ, Singh CL, Tan JY, Deng X, Hashemi Fard SM, Ng SYE, Ng ASL, Tan LCS, Saffari SE (2025) Common SNCA genetic variants and Parkinson\u2019s disease risk: a systematic review and meta-analysis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26136001","journal-title":"Int J Mol Sci"},{"issue":"8","key":"825_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1042\/cs20160802","volume":"131","author":"J Morel","year":"2017","unstructured":"Morel J, Hargreaves I, Brealey D, Neergheen V, Backman JT, Lindig S, Bl\u00e4ss M, Bauer M, McAuley DF, Singer M (2017) Simvastatin pre-treatment improves survival and mitochondrial function in a 3-day fluid-resuscitated rat model of sepsis. Clin Sci (Lond) 131(8):747\u2013758. https:\/\/doi.org\/10.1042\/cs20160802","journal-title":"Clin Sci (Lond)"},{"issue":"11","key":"825_CR24","doi-asserted-by":"publisher","first-page":"e1994","DOI":"10.1038\/cddis.2015.318","volume":"6","author":"LM Oliveira","year":"2015","unstructured":"Oliveira LM, Falomir-Lockhart LJ, Botelho MG, Lin KH, Wales P, Koch JC, Gerhardt E, Taschenberger H, Outeiro TF, Lingor P, Sch\u00fcle B, Arndt-Jovin DJ, Jovin TM (2015) Elevated \u03b1-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson\u2019s patient-derived induced pluripotent stem cells. Cell Death Dis 6(11):e1994. https:\/\/doi.org\/10.1038\/cddis.2015.318","journal-title":"Cell Death Dis"},{"issue":"1","key":"825_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddac161","volume":"32","author":"JD Prahl","year":"2023","unstructured":"Prahl JD, Pierce SE, van der Schans EJC, Coetzee GA, Tyson T (2023) The Parkinson\u2019s disease variant rs356182 regulates neuronal differentiation independently from alpha-synuclein. Hum Mol Genet 32(1):1\u201314. https:\/\/doi.org\/10.1093\/hmg\/ddac161","journal-title":"Hum Mol Genet"},{"key":"825_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2026.2669458","author":"L Ramos Dos Santos","year":"2026","unstructured":"Ramos Dos Santos L, Duplan E, Debord J, Fremont G, Minniti J, Lauritzen I, Mutez E, Leghay C, Chartier-Harlin MC, Checler F, Alves da Costa C (2026) PRKN\/parkin-mediated control of SNCA (synuclein alpha) and chaperone-mediated autophagy are defective in cellular, mice models and Parkinson disease-affected brains. Autophagy. https:\/\/doi.org\/10.1080\/15548627.2026.2669458","journal-title":"Autophagy"},{"key":"825_CR27","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.biopha.2017.04.038","volume":"90","author":"SS Saeedi Saravi","year":"2017","unstructured":"Saeedi Saravi SS, Saeedi Saravi SS, Khoshbin K, Dehpour AR (2017) Current insights into pathogenesis of Parkinson\u2019s disease: Approach to mevalonate pathway and protective role of statins. Biomed Pharmacother 90:724\u2013730. https:\/\/doi.org\/10.1016\/j.biopha.2017.04.038","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"825_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e41629","volume":"11","author":"Z Shi","year":"2025","unstructured":"Shi Z, Han S (2025) Personalized statin therapy: targeting metabolic processes to modulate the therapeutic and adverse effects of statins. Heliyon 11(1):e41629. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41629","journal-title":"Heliyon"},{"issue":"1","key":"825_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01803-1","volume":"12","author":"EK Shwab","year":"2024","unstructured":"Shwab EK, Gingerich DC, Man Z, Gamache J, Garrett ME, Crawford GE, Ashley-Koch AE, Serrano GE, Beach TG, Lutz MW, Chiba-Falek O (2024) Single-nucleus multi-omics of Parkinson\u2019s disease reveals a glutamatergic neuronal subtype susceptible to gene dysregulation via alteration of transcriptional networks. Acta Neuropathol Commun 12(1):111. https:\/\/doi.org\/10.1186\/s40478-024-01803-1","journal-title":"Acta Neuropathol Commun"},{"issue":"Pt 17","key":"825_CR30","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1242\/jeb.147058","volume":"220","author":"LU Sneddon","year":"2017","unstructured":"Sneddon LU, Halsey LG, Bury NR (2017) Considering aspects of the 3Rs principles within experimental animal biology. J Exp Biol 220(Pt 17):3007\u20133016. https:\/\/doi.org\/10.1242\/jeb.147058","journal-title":"J Exp Biol"},{"issue":"12","key":"825_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/NEN.0b013e31818e5e99","volume":"67","author":"S Theodore","year":"2008","unstructured":"Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67(12):1149\u20131158. https:\/\/doi.org\/10.1097\/NEN.0b013e31818e5e99","journal-title":"J Neuropathol Exp Neurol"},{"key":"825_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ani13020277","author":"P Verderio","year":"2023","unstructured":"Verderio P, Lecchi M, Ciniselli CM, Shishmani B, Apolone G, Manenti G (2023) 3Rs principle and legislative decrees to achieve high standard of animal research. Animals Basel. https:\/\/doi.org\/10.3390\/ani13020277","journal-title":"Animals Basel"},{"issue":"1","key":"825_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM (2011) Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72(1):57\u201371. https:\/\/doi.org\/10.1016\/j.neuron.2011.08.033","journal-title":"Neuron"},{"issue":"1","key":"825_CR34","doi-asserted-by":"publisher","first-page":"831","DOI":"10.18632\/aging.202189","volume":"13","author":"J Yan","year":"2020","unstructured":"Yan J, Huang J, Liu A, Wu J, Fan H, Shen M, Lai X, Ma H, Sun W, Yang J, Xu Y (2020a) Atorvastatin improves motor function, anxiety and depression by NOX2-mediated autophagy and oxidative stress in MPTP-lesioned mice. Aging (Albany NY) 13(1):831\u2013845. https:\/\/doi.org\/10.18632\/aging.202189","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"825_CR35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s10571-020-00804-7","volume":"40","author":"J Yan","year":"2020","unstructured":"Yan J, Liu A, Fan H, Qiao L, Wu J, Shen M, Lai X, Huang J (2020b) Simvastatin improves behavioral disorders and hippocampal inflammatory reaction by NMDA-mediated anti-inflammatory function in MPTP-treated mice. Cell Mol Neurobiol 40(7):1155\u20131164. https:\/\/doi.org\/10.1007\/s10571-020-00804-7","journal-title":"Cell Mol Neurobiol"},{"key":"825_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","volume":"18","author":"H Ye","year":"2023","unstructured":"Ye H, Robak LA, Yu M, Cykowski M, Shulman JM (2023) Genetics and Pathogenesis of Parkinson\u2019s Syndrome. Annu Rev Pathol 18:95\u2013121. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031521-034145","journal-title":"Annu Rev Pathol"},{"key":"825_CR37","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2022.12607","author":"J Zhang","year":"2022","unstructured":"Zhang J, Sun B, Yang J, Chen Z, Li Z, Zhang N, Li H, Shen L (2022) Comparison of the effect of rotenone and 1\u2011methyl\u20114\u2011phenyl\u20111,2,3,6\u2011tetrahydropyridine on inducing chronic Parkinson\u2019s disease in mouse models. Mol Med Rep. https:\/\/doi.org\/10.3892\/mmr.2022.12607","journal-title":"Mol Med Rep"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-026-00825-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12640-026-00825-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-026-00825-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:03:43Z","timestamp":1793300623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12640-026-00825-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1007\/s12640-026-00825-y","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal-related procedures reported in the present work were subject to review and approved by the Animal Experiment Ethics Committee of Guangzhou Medical University (2023028).","order":2,"name":"Ethics","label":"Ethics Approval\u00a0Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing intrests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"51"}}